Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437684 | 1.00 | PTGS2 (0.53) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL6437682 | 1.00 | PTGS2 (0.53) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL2008644 | 0.98 | PTGS2 (0.51) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL8670886 | 0.98 | PTGS2 (0.51) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL15688634 | 0.98 | PTGS2 (0.51) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL2008642 | 0.98 | PTGS2 (0.51) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL8670890 | 0.98 | PTGS2 (0.51) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL15688633 | 0.98 | PTGS2 (0.51) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL15689017 | 0.95 | PTGS2 (0.54) | PTGS2APPFBP1MAPTMEN1 | |
| SCHEMBL15689016 | 0.95 | PTGS2 (0.54) | PTGS2APPFBP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867323-B2 | Cross-coupling reaction of organosilicon nucleophiles | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | TST, HPD, PCNA | PTGS2 407/4885APP 4821/4885FBP1 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.